Compare ADMA Biologics Inc (ADMA) vs Alcon AG (ALC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Alcon AG — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Alcon AG trades at $72.42 (market cap $36.44B). The key difference: Alcon AG is far larger — about 16.4× ADMA Biologics Inc's market cap, and Alcon AG pays a 0.48% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ALC | |
|---|---|---|
Market Cap | $2.22B | $36.44B |
Sector | Health | Health |
52-Week High | $20.38 | $90.12 |
52-Week Low | $7.60 | $62.02 |
Enterprise Value | $2.29B | $40.28B |
Dividend Yield | — | 0.48% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →
